460 related articles for article (PubMed ID: 33382149)
1. PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Foo T; George A; Banerjee S
Genes Chromosomes Cancer; 2021 May; 60(5):385-397. PubMed ID: 33382149
[TBL] [Abstract][Full Text] [Related]
2. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
4. First-line PARP inhibitors in ovarian cancer: summary of an
Banerjee S; Gonzalez-Martin A; Harter P; Lorusso D; Moore KN; Oaknin A; Ray-Coquard I
ESMO Open; 2020 Nov; 5(6):e001110. PubMed ID: 33310779
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
6. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
7. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
8. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
Smith M; Pothuri B
Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
[TBL] [Abstract][Full Text] [Related]
9. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
10. The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
[TBL] [Abstract][Full Text] [Related]
11. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Le Saux O; Vanacker H; Guermazi F; Carbonnaux M; Roméo C; Larrouquère L; Trédan O; Ray-Coquard I
Future Oncol; 2021 Jun; 17(18):2291-2304. PubMed ID: 33726504
[TBL] [Abstract][Full Text] [Related]
13. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
14. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
[TBL] [Abstract][Full Text] [Related]
16. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
17. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George A; Kaye S; Banerjee S
Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
[TBL] [Abstract][Full Text] [Related]
18. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
19. Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Miller RE; Crusz SM; Ledermann JA
Future Oncol; 2019 Jun; 15(16):1845-1853. PubMed ID: 31037967
[TBL] [Abstract][Full Text] [Related]
20. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
